voriconazole inhaled (ZP-059) / Zambon - LARVOL DELTA

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Inhaled Voriconazole in Healthy Volunteers and Subjects With Stable Asthma. (PubMed, Pharmacol Res Perspect) - P1 | "The current study shows the newly developed dry powder inhaled formulation of voriconazole to be safe and well tolerated, providing a possible improved treatment approach for patients affected by allergic bronchopulmonary aspergillosis. Trial Registration: ClinicalTrials.gov ID: NCT04229303."

Clinical • Journal • P1 data • PK/PD data • Allergic Bronchopulmonary Aspergillosis • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: TFF Pharmaceuticals, Inc.

Clinical • New P1 trial • Asthma • Respiratory Diseases

Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects (clinicaltrials.gov) - P1; N=58; Completed; Sponsor: Zambon SpA; Recruiting ➔ Completed

Clinical • Trial completion • Asthma • Bronchopulmonary Dysplasia • Respiratory Diseases

Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects (clinicaltrials.gov) - P1; N=76; Recruiting; Sponsor: Zambon SpA; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open